News
Texas Sues Eli Lilly For Alleged Kickback Scheme Involving Mounjaro, Zepbound
Texas Attorney General Ken Paxton has filed a lawsuit against Eli Lilly and Co. (NYSE:LLY), accusing the pharmaceutical giant of bribing medical providers to promote its most profitable drugs, including the widely used GLP-1 medications Mounjaro and Zepbound for diabetes and weight loss.
Texas sues, accusing Eli Lilly of 'bribing' physicians to prescribe Zepbound, Mounjaro and other drugs
Paxton's office said the company supplied free nurses to help care for patients who received its drugs, as well as administrative support services that helped providers process insurance claims.
Eli Lilly on Wednesday launched the easy-to-use injector pen of its blockbuster weight-loss drug Mounjaro for 14,000 rupees ...
Despite posting record Q2 growth for its blockbuster weight loss and diabetes drug tirzepatide, Eli Lilly is facing legal ...
Eli Lilly (LLY) stock in focus as the company launches Mounjaro Kwikpen in India, intensifying competition with Novo ...
Eli Lilly has launched Mounjaro in KwikPen, a prefilled pen for weekly administration, in India to treat type 2 diabetes and ...
Eli Lilly has launched its Mounjaro KwikPen in India at ₹14,000 for the 2.5 mg dose; the once-weekly injector targets ...
Each KwikPen contains four doses, designed for single-patient use, and is priced between Rs14,000 and Rs 27,500 per month ...
Eli Lilly launches Mounjaro KwikPen in India, offering adults with type 2 diabetes and obesity a once-weekly, ...
Eli Lilly said it believes the new data bolsters the case for Mounjaro to be prescribers’ first choice for patients with Type ...
Eli Lilly and Company faces valuation pressure after disappointing Orforglipron results. Discover why now isn't the time to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback